ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

Breast

Volumn 23, Issue 5, 2014, Pages 489-502

  Cardoso, F ^a   Costa, A ^b,c   Norton, L ^d   Senkus, E ^e   Aapro, M ^f   Andre F ^g   Barrios, C H ^h   Bergh, J ⁱ   Biganzoli, L ^j   Blackwell, K L ^k   Cardoso, M J ^a   Cufer, T ^l   El Saghir, N ^m   Fallowfield, L ⁿ   Fenech, D ^o   Francis, P ^p   Gelmon, K ^q   Giordano, S H ^r   Gligorov, J ^s   Goldhirsch, A ^t   Harbeck, N ^u   Houssami, N ^v   Hudis, C ^d   Kaufman, B ^w   Krop, I ^x   Kyriakides, S ^y   Lin, U N ^x   Mayer, M ^z   Merjaver, S D ^aa   Nordstrom E B ^ab   Pagani, O ^ac   Partridge, A ^x   Penault Llorca, F ^ad   Piccart, M J ^ae   Rugo, H ^af   Sledge, G ^ag   Thomssen, C ^ah   van't Veer, L ^af   Vorobiof, D ^ai   Vrieling, C ^aj   West, N ^ak   Xu, B ^al   Winer, E ^x   more..

^a Champalimaud Cancer Center   (Portugal)

^b EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

^c European School of Oncology   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f Institut Multidisciplinaire d'Oncologie   (Switzerland)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j Sandro Pitigliani Medical Oncology Unit   (Italy)

^k DUKE CANCER INSTITUTE   (United States)

^l UNIVERSITY CLINIC OF RESPIRATORY AND ALLERGIC DISEASES   (Slovenia)

^m AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

ⁿ UNIVERSITY OF SUSSEX   (United Kingdom)

^o Europa Donna Malta   (Malta)

^p PETER MACCALLUM CANCER CENTRE   (Australia)

^q BRITISH COLUMBIA CANCER AGENCY   (Canada)

^r UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^s SORBONNE UNIVERSITÉ   (France)

^t EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^u UNIVERSITY OF MUNICH   (Germany)

^v UNIVERSITY OF SYDNEY   (Australia)

^w SHEBA MEDICAL CENTER   (Israel)

^x DANA FARBER CANCER INSTITUTE   (United States)

^y Europa Donna Cyprus   (Cyprus)

^z AdvancedBCorg   (United States)

^aa UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^ab Europa Donna Sweden and Bröstcancerföreningarnas Riksorganisation   (Sweden)

^ac ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^ad Jean Perrin Comprehensive Cancer Centre   (France)

^ae JULES BORDET INSTITUTE   (Belgium)

^af UNIVERSITY OF CALIFORNIA   (United States)

^ag INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^ah MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^ai Sandton Oncology Centre   (South Africa)

^aj Clinique et Fondation des Grangettes   (Switzerland)

^ak CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

^al CANCER HOSPITAL   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; PACLITAXEL; PERTUZUMAB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; TUMOR MARKER;

ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER CONTROL; CANCER GRADING; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; INFLAMMATORY BREAST CANCER; INOPERABLE CANCER; LIVER METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIPLE NEGATIVE BREAST CANCER; BREAST NEOPLASMS; FEMALE; INFLAMMATORY BREAST NEOPLASMS; METABOLISM; METASTASIS; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PATHOLOGY; PROCEDURES;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFLAMMATORY BREAST NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; QUALITY OF LIFE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84908126574     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2014.08.009     Document Type: Article

References (130)

1. Cardoso F. Metastatic breast cancer patients: the forgotten heroes!. Breast 2009, 18:271-272. [Editorial)].
2. Largillier R., Ferrero J.-M., Doyen J., Barriere J., Namer M., Mari V., et al. Prognostic factors in 1038 women with metastatic breast cancer. Ann Oncol 2008, 19:2012-2019.
3. Andre Fabrice, Slimane Khemaies, Bachelot Thomas, Dunant Arianne, Namer Moise, Barrelier Alain, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. JClin Oncol 2004, 22:3302-3308.
4. Sundquist M., Eriksson Z., Tejler G., Brudin L. Trends in survival in metastatic breast cancer. Eur J Cancer 2010, 8(3):191. [abstract 453].
5. Foukakis Theodoros, Fornander Tommy, Lekberg Tobias, Hellborg Henrik, Adolfsson Jan, Bergh Jonas Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat 2011, 10.1007/s10549-011-1594-z.
6. Fiteni F., Villanueva C., Bazan F., Perrin S., Chaigneau L., Dobi E., et al. Long-term follow-up of patients with metastatic breast cancer treated by trastuzumab: impact of institutions. The Breast 2014, 23(2):165-169.
7. Hébert-Croteau N., Brisson J., Latreille J., Rivard M., Abdelaziz N., Martin G. Compliance with consensus recommendations for systemic therapy is associated with improved survival of women with node-negative breast cancer. JClin Oncol 2004, 22(18):3685-3693.
8. Griggs J.J., Culakova E., Sorbero M.E., Poniewierski M.S., Wolff D.A., Crawford J., et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. JClin Oncol 2007, 25(18):2522-2527.
9. Hassett M.J., Hughes M.E., Niland J.C., Ottesen R., Edge S.B., Bookman M.A., et al. Selecting high priority quality measures for breast cancer quality improvement. Med Care 2008, 46(8):762-770.
10. Cardoso F., Costa A., Norton L., Cameron D., Cufer T., Fallowfield L., et al. 1st international consensus guidelines for advanced breast cancer (ABC1). Breast 2012, 21(3):242-252.
11. Metastatic breast cancer: recommendations proposal from the European school of oncology (ESO)-MBC task force. Breast 2007, 16:9-10.
12. Cardoso F., Bedard P.L., Winer E.P., Pagani O., Senkus-Konefka E., Fallowfield L.J., et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. JNatl Cancer Inst 2009, 101:1174-1181. On Behalf of the ESO-MBC Task Force. *Co-first authors.
13. Pagani Olivia, Senkus-Konefka Elzbieta, Wood William, Colleoni Marco, Cufer Tanja, Kyri-akides Stella, et al. International guidelines for management of metastatic breast cancer (MBC) from the European school of oncology (ESO)-MBC task force: can metastatic breast cancer be cured?. JNatl Cancer Inst 2010, 102:1-8. On Behalf of the ESO-MBC Task Force. *Co-first authors.
14. Lin Nancy U., Thomssen Christoph, Cardoso Fatima, Cameron David, Cufer Tanja, Fallowfield Lesley, et al. International guidelines for management of metastatic breast cancer (MBC) from the European school of oncology (ESO)-MBC task force: surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast 2013, 22(3):203-210. On Behalf of the ESO-MBC Task Force.
15. Guyatt G., Gutterman D., Baumann M.H., Addrizzo-Harris D., Hylek E.M., Phillips B., et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 2006, 129(1):174-181.
16. Freeman H.P. Patient navigation: a community centered approach to reducing cancer mortality. JCancer Educ 2006, 21(Suppl.1):S11-S14.
17. Freund K.M., Battaglia T.A., Calhoun E., Dudley D.J., Fiscella K., Paskett E., et al. National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures. Cancer 2008, 113(12):3391-3399.
18. Hopkins J., Mumber M.D. Patient navigation through the cancer care continuum: an overview. JOncol Pract 2009, 5(4):150-1525.
19. Robinson-White S., Conroy B., Slavish K.H., Rosenzweig M. Patient navigation in breast cancer: a systematic review. Cancer Nurs 2010, 33(2):127-140.
20. Ko N.Y., Darnell J.S., Calhoun E., Freund K.M., Wells K.J., Shapiro C.L., et al. Can patient navigation improve receipt of recommended breast cancer care? evidence from the national patient navigation research program. JClin Oncol 2014 Jul 28, pii: JCO.2013.53.6037. [Epub ahead of print].
21. Basch E. The missing voice of patients in drug-safety reporting. NEngl J Med March 11 2010, 362:865-869. 10.1056/NEJMp0911494.
22. Biganzoli L., Wildiers H., Oakman C., Marottu L., Loibl S., Reed M., et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Specialists (EUSOMA). Lancet Oncol 2012, 13:e148-e160.
23. Cardoso Fatima, Loibl Sibylle, Pagani Olivia, Graziottin Alessandra, Panizza Pietro, Martincich Laura, et al. The EUSOMA recommendations for the management of young women with breast cancer. Eur J Cancer 2012, 48(18):3355-3377.
24. Partridge Ann H., Pagani Olivia, Abulkhair Omalkhair, Aebi Stefan, Amant Frédéric, Azim Hatem A., et al. First international consensus guidelines for breast Cancer in young women (BCY1). Breast 2014, *Co-first authors; #Co-last authors, published online. http://dx.doi.org/10.1016/j.breast.2014.03.011.
25. Zimmermann C., Swami N., Krzyzanowska M., Hannon B., Leighl N., Oza A., et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014, 383(9930):1721-1730.
26. Ganz P.A., Yip C.H., Gralow J.R., Distelhorst S.R., Albain K.S., Andersen B.L., et al. Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast 2013, 22(5):606-615.
27. Cardoso F., Bese N., Distelhorst S.R., Bevilacqua J.L., Ginsburg O., Grunberg S.M., et al. Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast 2013, 22(5):593-605.
28. Silverman R., Smith L., Sundar S. 'Is it my last christmas dinner?' survival of cancer patients having palliative chemotherapy during christmas period. BMJ Support Palliat Care 2014 Mar, 4(Suppl.1):A56. 10.1136/bmjspcare-2014-000654.159.
29. El Saghir N.S., Adebamowo C.A., Anderson B.O., Carlson R.W., Bird P.A., Corbex M., et al. Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast 2011, 20(Suppl.2):S3-S11.
30. ® locally advanced breast cancer. Breast J 2011, 17(6):579-585.
31. Chia S., Swain S.M., Byrd D.R., Mankoff D.A. Locally advanced and inflammatory breast cancer. JClin Oncol 2008, 26:786-790.
32. Giordano S.H. Update on locally advanced breast cancer. Oncologist 2003, 8:521-530.
33. Yamauchi H., Woodward W.A., Valero V., Alvarez R.H., Lucci A., Buchholz T.A., et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist 2012, 17(7):891-899.
34. Brennan M.E., Houssami N. Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast 2012, 21:112-123.
35. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001 Mar 15, 344(11):783-792.
36. Buzdar A.U., Suman V., Bernstam F. ACOSOG Z1041 (Alliance): definitive analysis of randomized neoadjuvant trial comparing FEC followed by paclitaxel plus trastuzumab (FEC → P+T) with paclitaxel plus trastuzumab followed by FEC plus trastuzumab (P+T → FEC+T) in HER2+ operable breast cancer. JClin Oncol 2013, 31. suppl; abstr 502.
37. Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011, 29(17):2342-2349.
38. Cataliotti L., Buzdar A.U., Noguchi S., Bines J., Takatsuka Y., Petrakova K., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 2006, 106(10):2095-2103.
39. Ellis M.J., Ma C. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res Treat 2007, 105(Suppl.1):33-43.
40. Smith I.E., Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Blohmer J.U., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005, 23(22):5108-5116.
41. Loibl S., Volz C., Mau C., Blohmer J.U., Costa S.D., Eidtmann H., et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat 2014, 144(1):153-162.
42. Masuda N., Sagara Y., Kinoshita T., Iwata H., Nakamura S., Yanagita Y., et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol 2012, 13(4):345-352.
43. Sinacki M., Badzio A., Wełnicka-Jaśkiewicz M., Bogaerts J., Piccart M.J., Therasse P., et al. Pattern of care in locally advanced breast cancer: focus on local therapy. Breast 2011 Apr, 20(2):145-150.
44. Dawood S., Merajver S.D., Viens P., Vermeulen P.B., Swain S.M., Buchholz T.A., et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011, 22(3):515-523.
45. Cox C., Holloway C.M., Shaheta A., Nofech-Mozes S., Wright F.C. What is the burden of axillary disease after neoadjuvant therapy in women with locally advanced breast cancer?. Curr Oncol 2013, 20(2):111-117.
46. Byrski T., Gronwald J., Huzarski T., Grzybowska E., Budryk M., Stawicka M., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010, 28(3):375-379.
47. Byrski T., Huzarski T., Dent R., Gronwald J., Zuziak D., Cybulski C., et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009, 115(2):359-363.
48. Byrski T., Foszczynska-Kloda M., Huzarski T., Dent R., Gronwald J., Cybulski C., et al. Cisplatin chemotherapy in the treatment of BRCA1-positive metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15S). ASCO Annual Meeting Proceedings (Post-Meeting Edition). (May 20 Supplement), 2009: 1099.
49. Sikov WM, Berry DA, Perou CM, etal. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followeed by dose-dense AC on pathologic complete response in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance). Abstr. 2013 San Antonio breast Cancer symposium, S5-S01.
50. von Minckwitz G., Schneeweiss A., Loibl S., Salat C., Denkert C., Rezai M., et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014, 15(7):747-756.
51. Petrelli F., Coinu A., Borgonovo K., Cabiddu M., Ghilardi M., Lonati V., et al. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2014, 144(2):223-232.
52. Alba E., Chacon J., Lluch A., Anton A., Estevez L., Cirauqui B., et al. Arandomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat 2012, 136(2):487-493.
53. Koshy N., Quispe D., Shi R., Mansour R., Burton G.V. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 2010 Jun, 19(3):246-248.
54. Hemsell D.L., Grodin J.M., Brenner P.F., Siiteri P.K., MacDonald P.C. Plasma precursors of oestrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. JClin Endocrinol Metab 1974, 38:476-479.
55. Handesman D. Androgen actions and pharmacologic uses, Endocrinology 2001, 2232-2242. WB Saunders, Philadelphia.
56. Sousa B., Moser E., Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol 2013, 717:71-83.
57. Nordman I.C., Dalley D.N. Breast cancer in men-should aromatase inhibitors become first-line hormonal treatment?. Breast J 2008, 4:562-569.
58. Faneyte I.F., Turgers E.J., Zoetmulder F.A. Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer 1997, 80(5):886.
59. Schwaibold F., Fowble B.L., Solin L.J., Schultz D.J., Goodman R.L. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991, 21(2):299-310.
60. Skinner H.D., Strom E.A., Motwani S.B., Woodward W.A., Green M.C., Babiera G., et al. Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiat Oncol 2013, 8:13.
61. Müller A.C., Eckert F., Heinrich V., Bamberg M., Brucker S., Hehr T. Re-surgery and chest wall re-irradiation for recurrent breast cancer: a second curative approach. BMC Cancer 2011, 11:197.
62. Kilburn J.M., Kuremsky J.G., Blackstock A.W., Munley M.T., Kearns W.T., Hinson W.H., et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol 2014, 110(3):505-510.
63. Seiwer T.Y., Salama J.K., Vokes E.E. The concurrent chemoradiation paradigm- general principles. Nat Clin Pract 2007, 4(2):86.
64. Wilson G.D., Bentzen S.M., Harari P.M. Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006, 16(1):2-9.
65. Lawrence T.S., Tepper J.E., Blackstock A.W. Fluoropyrimidine-Radiation Interactions in Cells and Tumors. Semin Radiat Oncol 1997, 7(4):260-266.
66. Sawada N., Ishikawa T., Sekiguchi F., Tanaka Y., Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999, 5(10):2948-2953.
67. Crane C.H., Abbruzzese J.L., Evans D.B., Wolff R.A., Ballo M.T., Delclos M., et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys 2002, 52(5):1293-1302.
68. Liebmann J., Cook J.A., Fisher J., Teague D., Mitchell J.B. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994, 86(6):441-446.
69. González J.E., Barquinero J.F., Lee M., García O., Casaco A. Radiosensitization induced by the anti-epidermal growth factor receptor monoclonal antibodies cetuximab and nimotuzumab in A431 cells. Cancer Biol Ther 2012, 13(2):71-76.
70. Horton J.K., Halle J., Ferraro M., Carey L., Moore D.T., Ollila D., et al. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial. Int J Radiat Oncol Biol Phys 2010, 76(4):998-1004.
71. Löser D.A., Shibata A., Shibata A.K., Woodbine L.J., Jeggo P.A., Chalmers A.J. Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair. Mol Cancer Ther 2010, 9(6):1775-1787.
72. Jones E.L., Oleson J.R., Prosnitz L.R., Samulski T.V., Vujaskovic Z., Yu D., et al. Randomized trial of hyperthermia and radiation for superficial tumors. JClin Oncol 2005, 23:3079-3085.
73. Vernon C.C., Hand J.W., Field S.B., Machin D., Whaley J.B., van der Zee J., et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 1996, 35:731-744.
74. Zagar T.M., Higgins K.A., Miles E.F., Vujaskovic Z., Dewhirst M.W., Clough R.W., et al. Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. Radiother Oncol 2010, 97:535-540.
75. Borner M., Bacchi M., Goldhirsch A., Greiner R., Harder F., Castiglione M., et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. JClin Oncol 1994, 12(10):2071-2077.
76. Aebi S., Gelber S., Anderson S.J., Láng I., Robidoux A., Martín M. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol 2014, 15(2):156-163.
77. Robertson J.F., Osborne C.K., Howell A., Jones S.E., Mauriac L., Ellis M., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003 Jul 15, 98(2):229-238.
78. Howell A., Pippen J., Elledge R.M., Mauriac L., Vergote I., Jones S.E., et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 2005 Jul 15, 104(2):236-239.
79. Chia S., Gradishar W., Mauriac L., Bines J., Amant F., Federico M., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. JClin Oncol 2008, 26(10):1664-1670.
80. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., et al. Results of the confirm phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. JClin Oncol 2010, 28(30):4594-4600.
81. Johnston S.R., Kilburn L.S., Ellis P., Dodwell D., Cameron D., Hayward L., SoFEA Investigators, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013, 14(10):989-998.
82. Gibson L., Lawrence D., Dawson C., Bliss J. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009, (4):CD003370.
83. Bonneterre J., Thürlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000, 18(22):3748-3757.
84. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000, 18(22):3758-3767.
85. Milla-Santos A., Milla L., Portella J., Rallo L., Pons M., Rodes E., et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol 2003, 26(3):317-322.
86. Paridaens R., Dirix L., Lohrisch C., et al. European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC). Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003, 14:1391-1398.
87. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003, 21(11):2101-2109.
88. Paridaens R.J., Dirix L.Y., Beex L.V., Nooij M., Cameron D.A., Cufer T., et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008, 26(30):4883-4890.
89. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366(6):520-529.
90. Yardley D.A., Noguchi S., Pritchard K.I., Burris H.A., Baselga J., Gnant M., et al. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013, 30(10):870-884.
91. Piccart M., Hortobagyi G.N., Campone M., Pritchard K.I., Noguchi S., Rugo H., et al. Overall Survival Results From BOLERO-2. Presented at EBCC-9 2014, Everolimus Plus Exemestane for Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor-2-Negative (HER2-) Advanced Breast Cancer (BC) Abstract 1 LBA.
92. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30(22):2718-2724.
93. Gelmon K.A., Boyle F., Kaufman B., Huntsman D., Manikhas A., Di Leo A., et al. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 2012, 30. [suppl; abstr LBA671].
94. Pivot X., Zurawski B., Allerton R., Fabi A., Ciruelos E., Parikh R., et al. CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) versus trastuzumab plus capecitabine (TC); LBA11. Ann Oncol 2012, 23:ixe1-30.
95. Piccart-Gebhart M.J., Holmes A.P., Baselga J., De Azambuja E., Dueck A.C., Viale G., et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014, 32(5s). abstr LBA4.
96. Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366(2):109-119.
97. Swain S.M., Kim S.B., Cortés J., Ro J., Semiglazov V., Campone M., et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013, 14(6):461-471.
98. Cortés J., Fumoleau P., Bianchi G.V., Petrella T.M., Gelmon K., Pivot X., et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. JClin Oncol 2012 May 10, 30(14):1594-1600.
99. Blackwell K.L., Miles D., Gianni L., Krop I.E., Welslaw M., Baselga J., et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 2012, 30(5s). suppl; abstr LBA1.
100. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367(19):1783-1791.
101. Krop I.E., Kim S.B., González-Martín A., LoRusso P.M., Ferrero J.M., Smitt M., et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014, 15(7):689-699.
102. Dear R.F., McGeechan K., Jenkins M.C., Barratt A., Tattersall M.H.N., Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2013, (12). Art. No.: CD008792. 10.1002/14651858.CD008792.pub2.
103. Piccart-Gebhart M.J., Burzykowski T., Buyse M., Sledge G., Carmichael J., Lück H.J., et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. JClin Oncol 2008 Apr 20, 26(12):1980-1986.
104. Stockler M.R., Harvey V.J., Francis P.A., Byrne M.J., Ackland S.P., Fitzharris B., et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. JClin Oncol 2011, 29(34):4498-4504.
105. Blum J.L., Barrios C.H., Feldman N., Verma S., McKenna Lee LF., et al. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2012, 136(3):777-788.
106. Robert N.J., Diéras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29(10):1252-1260.
107. Oshaughnessy J.A., Blum J., Moiseyenko V., Jones S.E., Miles D., Bell D., et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001, 12(9):1247-1254.
108. Brufsky A.M., Hurvitz S., Perez E., Swamy R., Valero V., O'Neill V., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011, 29(32):4286-4293.
109. Talbot D.C., Moiseyenko V., Van Belle S., O'Reilly S.M., Alba Conejo E., Ackland S., et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002, 86(9):1367-1372.
110. Blum J.L., Jones S.E., Buzdar A.U., LoRusso P.M., Kuter I., Vogel C., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999, 17(2):485-493.
111. Blum J.L., Dieras V., Lo Russo P.M., Horton J., Rutman O., Buzdar A., et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001, 92(7):1759-1768.
112. Miller K.D., Chap L.I., Holmes F.A., Cobleigh M.A., Marcom P.K., Fehrenbacher L., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23(4):792-799.
113. Andersson Michael, Lidbrink Elisabeth, Bjerre Karsten, Wist Erik, Enevoldsen Kristin, Jensen Anders B., et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-Positive breast Cancer: the HERNATA study. JClin Oncol 2010, 29:264-271.
114. Burstein H.J., Keshaviah A., Baron A.D., Hart R.D., Lambert-Falls R., Marcom P.K., et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007 Sep 1, 110(5):965-972.
115. Cortes J., O'Shaughnessy J., Loesch D., Blum J.L., Vahdat L.T., Petrakova K., et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011 Mar 12, 377(9769):914-923.
116. Kaufman P.A., Awada A., Twelves C., Yelle L., Perez E.A., Wanders J., et al. Aphase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Cancer Res 2012, 72(Suppl.24). Abstract nr S6-6.
117. Dominici L., Najita J., Hughes M., Niland J., Marcom P., Wong Y.N., et al. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat 2011, 129(2):459-465.
118. Ly B.H., Nguyen N.P., Vinh-Hung V., Rapiti E., Vlastos G. Loco-regional treatment in metastatic breast cancer patients: is there a survival benefit?. Breast Cancer Res Treat 2010, 119(3):537-545.
119. Neuman H.B., Morrogh M., Gonen M., Van Zee K.J., Morrow M., King T.A. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter?. Cancer 2010, 116(5):1226-1233.
120. Rashaan Z.M., Bastiaannet E., Portielje J.E., van de Water W., van der Velde S., Ernst M.F., et al. Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery. Eur J Surg Oncol 2012, 38(1):52-56.
121. Ruiterkamp J., Ernst M.F. The role of surgery in metastatic breast cancer. Eur J Cancer 2011, 47(Suppl.3):S6-S22.
122. Nguyen D.H., Truong P.T., Alexander C., Walter C.V., Hayashi E., Christie J., et al. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis?. Int J Radiat Oncol Biol Phys 2012, 84(1):39-45.
123. Petrelli F., Barni S. Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regression. Med Oncol 2012, 29:3282-3290.
124. Ruiterkamp J., Voogd A.C., Tjan-Heijnen V.C., Bosscha K., van der Linden Y.M., Rutgers E.J., et al. SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation. BMC Surg 2012 Apr 2, 12:5.
125. Shien T., Nakamura K., Shibata T., Kinoshita T., Aogi K., Fujisawa T., et al. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Jpn J Clin Oncol 2012, 42(10):970-973.
126. Badwe R., Parmar V., Hawaldar R., Nair N., Kaushik R., Siddique S., et al. Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: a randomized controlled trial. Cancer Res 2013, 73(Suppl.24). S2-S02.
127. Soran Atilla, Ozmen Vahit, Ozbas Serdar, Karanlik Hasan, Muslumanoglu Mahmut, Igci Abdullah, et al. Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish Study (Protocol MF07-01). Cancer Res 2013, 73(Suppl.24). S2-02.
128. Thompson A.M., Jordan L.B., Quinlan P., Anderson E., Skene A., Dewar J.A., et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 2010, 12(6):R92.
129. Amir E., Clemons M., Purdie C.A., Miller N., Quinlan P., Geddie W., et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 2012, 38(6):708-714.
130. Foukakis T., Åström G., Lindström L., Hatschek T., Bergh J. When to order a biopsy to characterise a metastatic relapse in breast cancer. Ann Oncol 2012, 23(Suppl.10):x349-x353.